Bortezomib
Gastroesophageal Junction Cancer
Novartis PharmaceuticalsSmall moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Gastroesophageal Junction Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
azd0901 AstraZeneca | Phase 2 | CCC |
Irinotecan AstraZeneca | Phase 2 | CCC |
azd4360 AstraZeneca | Phase 1/2 | CCC |
azd7789 AstraZeneca | Phase 1/2 | CC |
BKM120 Novartis Pharmaceuticals | Phase 1 | CC |
Incagn02390 Incyte Corporation | Phase 1 | CC |
pf-07265028 Pfizer | Phase 1 | CC |
Sasanlimab Pfizer | Phase 1 | D |
Same molecule, other indications
Bortezomib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →